Diamedica Inc.

Monthly archive

Press Releases - 2007

DiaMedica receives regulatory clearance for Phase II human study of DM-83

Posted by admin on Dec, 13 2007

 WINNIPEG, Manitoba – December 13, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes is pleased to announce that it has received regulatory clearance from the Office for Registration of Medicinal Products, Medicinal Devices and Biocidal Products, of Poland, to conduct a Phase II human study with DM-83 in type 2 diabetes patients.

DM-83 Restores Meal Associated Insulin Sensitivity in Pre-clinical Study

Posted by admin on Dec, 6 2007

 WINNIPEG, Manitoba – December 6, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes is pleased to announce final pre-clinical data for DM-83, its second clinical drug candidate. In the study, meal associated insulin sensitivity (MIS) was restored to normal levels by DM-83 with high statistical significance (p=0.001).

DiaMedica Named One of Canada's Top 10 Life Science Companies

Posted by admin on Dec, 3 2007

 WINNIPEG, Manitoba - December 3, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, is pleased to announce that it has been named as one of Canada's Top 10 Life Science Companies.

DiaMedica completes data analysis of DM-71 Phase II trial and updates development plan

Posted by admin on Oct, 29 2007

 WINNIPEG, Manitoba – November 29, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes is pleased to report on the final data conclusions from its 12 week, Phase II proof-of-concept study with DM-71, including previously unreported data related to fructosamine and safety markers, and outlines its continued development program for DM-71.

DiaMedica announces formation of European subsidiary

Posted by admin on Oct, 27 2007

 WINNIPEG, Manitoba – November 22, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes today announces the formation of DiaMedica Europe Ltd. in the United Kingdom.    DiaMedica Europe Ltd. was formed to facilitate the performance of clinical studies in the European Union and is a wholly owned subsidiary of DiaMedica Inc.

DiaMedica announces exciting phase II results for DM-71 in type 2 diabetes trial

Posted by admin on Oct, 1 2007

 WINNIPEG, Manitoba – October 1, 2007 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, is pleased to announce exciting results for DM-71 in its proof-of-concept phase II clinical study in type 2 diabetes. 

DiaMedica to Present at BioContact Quebec 2007

Posted by admin on Sep, 27 2007

 WINNIPEG, Manitoba – September 27, 2007 - DiaMedica Inc. (TSX-V: DMA), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, will present at the upcoming BioContact Quebec 2007 Conference.  The presentation will take place on Wednesday October 3rd, 2007 at 4:00 pm (Eastern Time) at the Chateau Frontenac Hotel in Quebec City.

DiaMedica Announces Positive Pre-Clinical Results for DM-83

Posted by admin on Sep, 18 2007

 WINNIPEG, Manitoba – September 18, 2007 - DiaMedica Inc. (TSX-V: DMA), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce positive pre-clinical data for DM-83, its second clinical drug candidate.

DiaMedica announces DiaMedica provides update on phase II clinical study of DM-71 in type 2 diabetes

Posted by admin on Jul, 16 2007

 WINNIPEG, Manitoba – DiaMedica Inc. (TSX-V:DMA) – July 16, 2007 – DiaMedica Inc. (TSX-V:DMA), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce that the final patient has completed the treatment period in its phase II study evaluating DM-71 in the treatment of type 2 diabetes.

DiaMedica completes patient enrollment in phase II clinical study of DM-71 in type 2 diabetes

Posted by admin on Apr, 11 2007

 WINNIPEG, Manitoba – DiaMedica Inc. (TSX-V:DMA), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce that it has admitted the 80th and final patient and completed enrollment in its phase II study evaluating DM-71 in the treatment of type 2 diabetes. The Company expects to announce the results of the study in the second half of 2007.

 

DiaMedica appoints David Allan to its board of directors

Posted by admin on Mar, 26 2007

 WINNIPEG, Manitoba – March 26, 2007 – DiaMedica Inc. (the “Company” or “DiaMedica”) (TSX-V:DMA), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce that subject to regulatory approval, David G.P. Allan has joined its board of directors. Mr. Allan is well known in the life sciences and investment banking industries and has considerable experience in the public markets.

 

DiaMedica announces closing of its initial public offering and listing on TSX Venture Exchange as “DMA”

Posted by admin on Mar, 22 2007

 WINNIPEG, Manitoba – DiaMedica Inc. (TSX-V:DMA), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce that it has successfully completed its initial public offering of common shares. DiaMedica’s shares will begin trading on the TSX Venture Exchange today under the symbol “DMA”.